Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 Jul 29;22(11):2092–2099. doi: 10.1016/j.bbmt.2016.07.014

Table 2.

Use of Additional Transplantation Strategies

Response Post Cy Donor NK cells CMV T Cells DEXA Allo
No, do not recommend 101 of 267 (37.8%) 243 of 267 (91.0%) 187 of 266 (70.3%) 190 of 266 (71.4%)
Yes, on/off trials and within trial 166 of 267 (62.2%) 24 of 267 (9.0%) 79 of 266 (29.7%) 76 of 266 (28.6%)

Post Cy indicates post-transplantation cyclophosphamide for GVHD prophylaxis; Donor NK cells, haploidentical donor natural killer cells for post-transplantation relapse prevention; CMV T cells, cytomegalovirus-specific T cells for refractory cytomegalovirus infection; DEXA allo, screening and prevention strategies for post-transplantation bone density loss.